Rate My Professor Paul Griffin

Associate Professor Paul Griffin serves as the Director of Infectious Diseases at Mater Health Services in Brisbane, appointed in 2013, and as Associate Professor of Medicine at the University of Queensland Medical School. He holds fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia, and from the Australasian College of Tropical Medicine. Griffin is also Principal Investigator and Medical Director at Nucleus Network, where he has overseen more than 125 clinical trials focused on infectious diseases, including novel vaccines, malaria human challenge studies, eight COVID-19 vaccines, and COVID-19 therapies. As a clinical microbiologist, he maintains interests in diagnostic microbiology, particularly clinical applications of faecal microbiome metagenomic sequencing.

Griffin's research specializations lie in infectious diseases, vaccine development, antimalarial therapies, and pathogen detection. He chairs the Advanced Training Committee in Infectious Diseases for the Royal Australasian College of Physicians, which oversees training for specialists in Australia, and is a director and scientific advisory board member of the Immunisation Coalition, contributing to vaccine education and advocacy. Key publications include 'Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study' (2025, The Lancet Infectious Diseases); 'Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose' (2024, The Lancet Infectious Diseases); 'Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine' (2020, The New England Journal of Medicine); chapters in Kucers’ The Use of Antibiotics on niclosamide, furazolidone, and diloxanide furoate (2017 and 2010 editions); and 'Safety and reproducibility of a clinical trial system using induced blood-stage Plasmodium vivax infection' (2016, PLoS Neglected Tropical Diseases). He has emerged as a trusted national media spokesperson on infectious diseases, microbiology, vaccines, and the COVID-19 pandemic, appearing on programs such as The Project, Sunrise, Today Show, A Current Affair, CTV Canada, and BBC.